linkedin facebook youtube
search
back

Clinical Trials

  • ESLICARBAZEPINE ACETATE
  • Opicapona
  • Zamicastat
57 results of Eslicarbazepine Acetate
STUDY CODE
CLINICALTRIALS.GOV
EUDRACT
PUBLICATIONS
PHASE I Studies
BIA-2093-101  
NCT02171195
-
DOI:10.2165/00126839-200304050-00001
BIA-2093-102  
NCT02171234
-
DOI: 10.1177/0091270004267591
BIA-2093-103  
NCT02170649
-
DOI: 10.2165/00126839- 200506040-00002
BIA-2093-104  
NCT01678976
-
-
BIA-2093-105  
NCT02172755
-
DOI: 10.1177/0091270005279364 DOI: 10.1002/bdd.549
BIA-2093-106  
NCT01878578
-
-
BIA-2093-107  
NCT02172742
-
DOI: 10.1111/j.1472- 8206.2009.00691.x
BIA-2093-108  
NCT02287415
-
DOI: 10.1016/j.clinthera.2010.01.014
BIA-2093-109  
NCT02279667
-
DOI: 10.2165/00126839- 200506050-00001
BIA-2093-110  
NCT01679002
-
DOI: 10.1111/epi.12242
BIA-2093-111  
NCT02281526
-
DOI: 10.1007/s00228-007-0414-1
BIA-2093-112  
NCT02281422
-
DOI 10.5414/CPP46119
BIA-2093-113  
NCT01879345
2004-002994-22
-
BIA-2093-114  
NCT02281448
2004-004490-28
DOI: 10.1016/j.eplepsyres.2013.02.020
BIA-2093-115  
NCT02281591
2005-006016-22
-
BIA-2093-116  
NCT02283788
-
DOI: 10.1177/0091270010391789
BIA-2093-117  
NCT02288312
2007-000714-36
DOI: 10.2165/0126839- 200809060-00007
BIA-2093-118  
NCT01879332
-
-
BIA-2093-119  
NCT02283801
-
DOI: 10.1111/j.1600- 0404.2009.01233.x
BIA-2093-120  
NCT02283814
-
DOI: 10.1185/03007991003740861
BIA-2093-121  
NCT02283827
-
DOI: 10.1111/j.1528- 1167.2012.03519.x
BIA-2093-122  
NCT02283840
-
DOI:10.4172/jbb.1000014
BIA-2093-123  
NCT02284828
-
DOI: 10.1016/j.yebeh.2010.04.022
BIA-2093-124  
NCT00987558
2009-012211-18
DOI: 10.1016/j.eplepsyres.2013.04.009
BIA-2093-125  
NCT00971295
2007-003953-94
DOI 10.5414/CPP47255
BIA-2093-126  
NCT02777671
2007-003954-27
-
BIA-2093-127  
NCT00900237
2008-004800-30
DOI: 10.1111/j.1528- 1167.2012.03595.x
BIA-2093-128  
NCT00898560
2007-006529-28
DOI: 10.1016/j.eplepsyres.2013.02.020
BIA-2093-129  
NCT02284854
2009-012550-21
DOI: 10.1111/j.1528- 1167.2012.03519.x
BIA-2093-130  
NCT02284880
2010-022478-15
DOI: 10.1007/s40268-013-0016-6
BIA-2093-131  
NCT03116321
-
-
BIA-2093-132  
 
2018-001484-23
 
PHASE II Studies
BIA-2093-201  
NCT02170077
-
DOI: 10.1111/j.1528- 1167.2007.00984.x
BIA-2093-202  
NCT02170064
-
DOI: 10.1177/0091270008319706
BIA-2093-203  
NCT01822678
2005-002131-27
DOI: 10.1016/j.jad.2014.11.013
BIA-2093-204  
NCT01824602
2005-002133-13
DOI: 10.1016/j.jad.2014.11.013
BIA-2093-205  
NCT01825837
2005-002134-35
DOI: 10.1016/j.jad.2014.11.013
BIA-2093-206  
NCT00980746
2007-002461-12
-
BIA-2093-207  
NCT00981227
2007-002473-31
-
BIA-2093-208  
NCT01527513
2008-005606-39
-
BIA-2093-209  
NCT01820559
2008-003736-38
-
BIA-2093-210  
NCT01820585
2008-003557-32
-
BIA-2093-211  
-
2012-001091-11
-
BIA-2093-211/EXT  
-
2016-001072-29
-
BIA-2093-212  
NCT02021461
2012-003137-41
-
BIA-2093-213  
-
2018-002747-29
-
PHASE III Studies
BIA-2093-301  
NCT00957684
2004-000766-12
DOI: 10.1111/j.1528- 1167.2008.01946.x
DOI: 10.1111/j.1528-1167.2010.02660.x
DOI: 10.1016/j.eplepsyres.2011.05.013
DOI: 10.2165/11596290-000000000-00000
DOI: 10.1111/j.1528-1167.2012.03605.x
BIA-2093-302  
NCT00957047
2004-000483-27
DOI: 10.1016/j.eplepsyres.2010.01.014
DOI: 10.1016/j.eplepsyres.2012.07.014
DOI: 10.2165/11596290-000000000-00000
DOI: 10.1111/j.1528-1167.2012.03605.x
BIA-2093-303  
NCT00957372
2004-001748-66
DOI: 10.1111/j.1600- 0404.2009.01218.x
DOI: 10.2165/11596290- 000000000-00000
DOI: 10.1111/j.1528- 1167.2012.03605.x
BIA-2093-304  
NCT00988429
2008-002455-25
DOI: 10.1016/j.yebeh.2015.09.018
DOI: 10.1111/epi.12894
BIA-2093-305  
NCT00988156
2007-001887-55
DOI:https://doi.org/10.1016/j.yebeh.2020.106962
BIA-2093-307  
NCT01129960
2010-019100-23
-
BIA-2093-308  
NCT01124097
2010-019101-42
-
BIA-2093-311  
NCT01162460
2009-011135-13
DOI: 10.1111/epi.13993
BIA-2093- 311/EXT  
NCT02484001
2015-001243-36
https://doi.org/10.1111/epi.16666
PHASE IV Studies
BIA-2093-401  
NCT01422720
2009-012587-14
DOI: 10.1007/s40266-018-0602-y
BIA-2093-403  
NCT01532726
-
doi: 10.1111/ane.12734
42 results of Opicapone
STUDY CODE
CLINICALTRIALS.GOV
EUDRACT
PUBLICATIONS
PHASE I Studies
BIA-91067-101  
NCT01520727
2007-004161-18
DOI: 10.1007/s40262-012-0024-7
BIA-91067-102  
NCT02071810
2008-001288-12
DOI: 10.1111/bcp.12081
BIA-91067-103  
NCT01515891
-
-
BIA-91067-104  
NCT02071823
-
DOI: 10.1007/s40262-012-0024-7
BIA-91067-105  
NCT02092168
2008-005145-35
-
BIA-91067-106  
NCT02101190
2009-015899-10
DOI: 10.1007/s00228-013-1602-9
BIA-91067-107  
NCT02169895
-
-
BIA-91067-108  
NCT02169479
-
-
BIA-91067-109  
NCT02169466
2008-003289-25
-
BIA-91067-110  
NCT02169453
-
-
BIA-91067-111  
NCT01532115
2010-019240-40
DOI: 10.1002/cpdd.188
BIA-91067-112  
NCT01532128
2009-016073-15
-
BIA-91067-113  
NCT01532141
2009-016074-32
-
BIA-91067-114  
NCT01519284
2009-014549-94
-
BIA-91067-115  
NCT01536366
2009-011449-24
-
BIA-91067-116  
NCT02169440
2009-010765-24
-
BIA-91067-117  
NCT01533077
-
-
BIA-91067-118  
NCT01533116
-
DOI: 10.1111/bcp.13156
BIA-91067-119  
NCT02305277
2014-000267-41
-
BIA-91067-120  
NCT02305316
2013-004775-12
-
BIA-91067-121  
NCT02305329
2014-000225-21
-
BIA-91067-122  
NCT02169427
2011-000298-30
-
BIA-91067-123  
NCT02169414
2009-018138-13
DOI: 10.1111/bcp.13156
BIA-91067-124  
NCT02170376
2011-000173-31
DOI: 10.1007/s00228-014-1701-2
BIA-91067-125  
NCT02305017
2013‐003871‐37
-
BIA-91067-126  
NCT01520987
-
DOI: 10.1002/cpdd.213
BIA-91067-127  
NCT02305030
2014-000205-13
-
BIA-91067-128  
NCT03116308
2014-001626-15
-
BIA-91067-129  
NCT03116295
2017-000857-37
-
BIA-91067-130  
NCT03119194
2016-004454-15
-
BIA-91067-131  
NCT04265027
2017-004680-13
-
BIA-91067-132  
NCT03820037
2018-004748-45
-
PHASE II Studies
BIA-91067-201  
NCT01568034
2008-003869-72
DOI: 10.1002/cpdd.217
BIA-91067-202  
NCT01568047
2009-012897-12
DOI: 10.1111/ene.12666
PHASE III Studies
BIA-91067-301  
NCT01568073
2010-021860-13
DOI: 10.1016/S1474-4422(15)00336-1
DOI: 10.3233/JPD-191593
BIA-91067-302  
NCT01227655
2010-022366-27
DOI: 10.1001/jamaneurol.2016.4703
DOI: 10.3233/JPD-191593
BIA-91067-303  
-
2020-005011-52
-
PHASE IV Studies
BIA-OPC-401  
NCT02847442
2016-002391-27
DOI: 10.1186/s40035-020-00187-1
BIA-91067-402  
NCT03959540
-
-
BIA-91067-403  
-
2020-002754-24
-
BIA-91067-404  
-
2020-001175-32
-
BIA-91067-405  
-
2020-001176-15
-
21 results of Zamicastat
STUDY CODE
CLINICALTRIALS.GOV
EUDRACT
PUBLICATIONS
PHASE I Studies
BIA-51058-101  
NCT02151994
2010-023490-19
https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3816
BIA-51058-102  
-
2015-001951-65
-
BIA-51058-104  
-
2015-002407-28
-
BIA-51058-105  
-
2015-003682-28
-
BIA-51058-106  
-
2017-000245-43
-
BIA-51058-107  
-
2015-004350-17
https://journal.chestnet.org/article/S0012-3692(20)31303-9/fulltext
BIA-51058-108  
-
2017-000224-99
https://erj.ersjournals.com/content/56/suppl_64/1458
BIA-51058-109  
-
2015-004351-49
https://journal.chestnet.org/article/S0012-3692(20)34114-3/fulltext
BIA-51058-110  
-
2020‐000224‐18
-
BIA-51058-111  
-
2017-002807-93
-
BIA-51058-113  
-
2017-003518-23
-
BIA-51058-114  
-
2017-003519-20
-
BIA-51058-115  
NCT03489005
2017-001682-25
https://doi.org/10.1164/ajrccm-conference.2020.201.1_MeetingAbstracts.A3815
BIA-51058-116  
NCT03708146
2018-000113-20
-
BIA-51058-117  
-
-
-
BIA-51058-118  
-
-
-
BIA-51058-119  
NCT04069130
2018-003995-11
-
BIA-51058-121  
-
2020‐002317‐17
-
PHASE II Studies
BIA-51058-201  
NCT04316143
2018-002448-10
-
BIA-51058-202  
-
2018-002796-18
-
BIA-51058-203  
-
2021-001518-12
-

You are now navigating away from the BIAL website.

BIAL takes responsibility for its website contents. By clicking “continue” below, you will be taken to an external website, beyond our responsibility.

CANCEL CONTINUE
image